- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00765674
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
April 15, 2011 updated by: Novartis
An 8 Week, Double-blind, Randomized, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate to Severe Hypertension
This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1191
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Sydney, Australia
- Investigative Site
-
-
-
-
-
Ottawa, Canada
- Investigative Site
-
-
-
-
-
Copenhagen, Denmark
- Investigative Site
-
-
-
-
-
Berlin, Germany
- Investigative Site
-
-
-
-
-
Jerusalem, Israel
- Investigative Site
-
-
-
-
-
Rome, Italy
- Investigative Site
-
-
-
-
-
Riga, Latvia
- Investigative Site
-
-
-
-
-
Vilnius, Lithuania
- Investigative Site
-
-
-
-
-
Bucharest, Romania
- Investigative Site
-
-
-
-
-
Stockholm, Sweden
- Investigative Site
-
-
-
-
-
Ankara, Turkey
- Investigative Site
-
-
-
-
Colorado
-
Denver, Colorado, United States
- Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female
- 18 years of age or older
msDBP and msSBP requirements:
3A:
- Diagnosis of moderate to severe hypertension (msSBP ≥ 160 mmHg and < 200 mmHg, and/or msDBP ≥ 100 mmHg and < 120 mmHg) at Visits 4, 5 or 6 (Qualifying BP visit)
- In addition, at the visit immediately prior to the above qualifying visit, patients were also to have msSBP ≥ 145 mmHg and < 200 mmHg and msDBP ≥ 95 mmHg and < 120 mmHg) at Visits 3, 5 or 5.
- Patients had to meet the above two sets of requirements at subsequent adjacent visits, i.e. either Visits 3 and 4, Visits 4 and 5, or Visits 5 and 6.
- OR
3B:
- msSBP ≥ 180 mmHg and < 200 mmHg with msDBP ≥ 95 mmHg and < 120 mmHg, or msDBP ≥ 110 mmHg and < 120 mmHg with msSBP ≥ 150 mmHg and < 200 mmHg after at least one week of treatment with placebo (Visit 3 and on).
Exclusion Criteria:
- Continued use of anti-hypertensive medicines or use of 4 or more hypertensive medicines at study start
- Patients with an msSBP ≥ 200 mmHg or msDBP ≥ 120 mmHg at any time during the placebo run-in period were to be discontinued from the study.
- Extremely elevated (defined) blood pressure at any point during the study
- Pregnant or lactating women
- Pre-menopausal women not taking accepted form of birth control
- History or evidence of secondary form of hypertension
- History of cardiovascular conditions
Other protocol-defined inclusion/exclusion criteria applied to the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Aliskiren / amlodipine
Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study.
During the 8 weeks, patients also received a placebo tablet and a placebo capsule.
Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
|
capsules
tablet
150 and 300 mg tablets
5 and 10 mg capsules
|
Experimental: Aliskiren / hydrochlorothiazide
Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study.
During the 8 weeks, patients also received a placebo capsule and a placebo tablet.
Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
|
capsules
tablet
150 and 300 mg tablets
12.5 and 25 mg capsules
|
Experimental: Amlodipine / hydrochlorothiazide
Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study.
During the 8 weeks, patients also received 2 placebo tablets.
Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
|
capsules
tablet
5 and 10 mg capsules
12.5 and 25 mg capsules
|
Experimental: Aliskiren / amlodipine / hydrochlorothiazide
Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment.
Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment.
At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study.
During the 8 weeks, patients also received a placebo tablet.
Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.
|
capsules
tablet
150 and 300 mg tablets
5 and 10 mg capsules
12.5 and 25 mg capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
Time Frame: Baseline to end of study (Week 8)
|
Blood pressure (BP) was measured at trough (24±3 hours post-dose).
The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings.
If there was < 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used.
At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff.
Means of the 3 measurements were calculated.
A negative change indicates lowered BP.
|
Baseline to end of study (Week 8)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
Time Frame: Baseline to end of study (Week 8)
|
Blood pressure (BP) was measured at trough (24±3 hours post-dose).
The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings.
If there was < 0.5 mmHg difference in BP between the 2 arms, the non-dominant arm was used.
At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff.
Means of the 3 measurements were calculated.
A negative change indicates lowered BP.
|
Baseline to end of study (Week 8)
|
Percentage of Patients Achieving Blood Pressure Control at the End of the Study (Week 8)
Time Frame: End of study (Week 8)
|
Blood pressure control was defined as a msSBP/msDBP < 140/90 mmHg at the end of the study (Week 8).
Blood pressure (BP) was measured at trough (24±3 hours post-dose).
The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings.
At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff.
Means of the 3 measurements were calculated.
|
End of study (Week 8)
|
Change in Mean 24-hour Ambulatory Systolic and Diastolic Blood Pressure From Baseline to End of Study (Week 8)
Time Frame: Baseline to end of study (Week 8)
|
Twenty-four hour ambulatory blood pressure monitoring (ABPM) was performed in a subset of patients twice during the study, once at baseline and again at Week 8.
The ABPM device was placed on the non-dominant arm between 7:00 and 10:00 am and verification readings obtained.
If they were successful, the investigator initiated the 24 hour reading and instructed the patient regarding ABPM procedures.
On the next day, the ABPM device was removed if it had been worn for a minimum of 24 hours.
The ABPM data were downloaded and evaluated on site.
|
Baseline to end of study (Week 8)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2008
Primary Completion (Actual)
August 1, 2009
Study Completion (Actual)
August 1, 2009
Study Registration Dates
First Submitted
October 2, 2008
First Submitted That Met QC Criteria
October 2, 2008
First Posted (Estimate)
October 3, 2008
Study Record Updates
Last Update Posted (Estimate)
May 9, 2011
Last Update Submitted That Met QC Criteria
April 15, 2011
Last Verified
April 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Sodium Chloride Symporter Inhibitors
- Amlodipine
- Hydrochlorothiazide
Other Study ID Numbers
- CSAH100A2302
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BayerCompletedPrimary HypertensionChina
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Addpharma Inc.Completed
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Istituto Auxologico ItalianoRecruitingHypertension,Essential | Hypertension, UncontrolledArgentina, China
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States